Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A first-in-class drug called telitacicept is showing impressive staying power in patients with generalized myasthenia gravis (gMG). A post hoc analysis of a phase 3 trial found that ~42% of patients achieved near-symptom-free status by week 48, with benefits deepening the longer patients stayed on the drug. A global phase 3 trial is underway, with results expected in early 2027.
A first-in-class B-cell therapy is turning heads in the myasthenia gravis (MG) world. Telitacicept — a fusion protein that blocks two key drivers of B-cell survival and antibody production — showed deep and durable benefits in patients with generalized MG (gMG) over 48 weeks, according to a post hoc analysis of a phase 3 trial presented at AANEM 2026.
The drug works by targeting B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), offering broader immune control than therapies that hit downstream pathways. Patients self-administer it weekly via subcutaneous injection — a practical plus for a chronic condition.
By the Numbers:
Why it matters: Myasthenia gravis is a debilitating autoimmune disease with a rapidly expanding treatment landscape. Telitacicept's ability to produce deepening, sustained responses — including near-complete symptom relief in a meaningful share of patients — could make it a strong contender in the MG toolkit, pending results from its ongoing global phase 3 trial expected in early 2027.
